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original work is propObjectives: Evaluate long-term rates of virological failure and treatment interruption
for people living with HIV (PLWHIV) with viral suppression on first-line efavir-
enzþ tenofovir disoproxil fumarateþ emtricitabine/lamivudine (EFVþTDFþ FTC/
3TC), and compare these according to patient characteristics.
Methods: PLWHIV enrolled in the Collaboration of Observational HIV Epidemiologi-
cal Research Europe cohort collaboration, who started first-line EFVþTDFþ FTC/3TC
at age at least 16 years and had viral suppression (<200 copies/ml) within 9 months
were included. Rates of virological failure (200 copies/ml) and (complete) treatment
interruption were estimated according to years since initial suppression. We used
Poisson regression to examine associations of baseline characteristics with rates of
virological failure or treatment interruption.
Results: Among 19527 eligible PLWHIV with median (interquartile range) follow-up
3.7 (2.0–5.6) years after initial viral suppression, the estimated rate of the combined
incidence of virological failure or treatment interruption fell from 9.0/100 person-years
in the first year to less than 4/100 person-years beyond 3 years from suppression;
considering only those remaining on EFVþTDFþ FTC/3TC, the combined rate dropped
from 8.2/100 person-years in the first year to less than 3.5/100 person-years beyond 3
years. PLWHIV with injecting drug-related or heterosexual transmission were at higher
risk of virological failure or treatment interruption, as were those of Black ethnicity.
PLWHIV aged less than 35 years were at higher risk of virological failure and treatment
interruption.
Conclusion: PLWHIV starting first-line EFVþTDFþ FTC/3TC had low rates of
virological failure and treatment interruption up to 10 years from initial suppression.
Demographic characteristics can be used to identify subpopulations with higher risks of
these outcomes.
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746 AIDS 2019, Vol 33 No 4IntroductionThe combination of efavirenz (EFV), tenofovir disoproxil
fumarate (TDF) and emtricitabine (FTC) or lamivudine
(3TC) was established as preferred first-line antiretroviral
therapy (ART) for HIV in 2013 WHO guidelines [1].
However, first-line EFV is no longer the preferred choice
in most patients [2] because of the availability of new
combinations with greater efficacy and fewer side effects
and emergence of high levels of transmitted resistance to
nonnucleoside/nucleotide reverse transcriptase inhibitors
in some low/middle income countries (LMICs) [3].
Despite reductions in newly diagnosed people living with
HIV (PLWHIV) starting EFVþTDFþ FTC/3TC, large
numbers remain on this regimen [4] and so there is a need
to evaluate its long-term effectiveness.
An analysis from the UK Collaborative HIV Cohort (UK
CHIC) Study showed that PLWHIV on ART regimens
with initial viral suppression have annual rates of
virological rebound (200 copies/ml threshold) that
decrease from around 9/100 person-years in the first
year to less than 3/100 person-years after some years on
treatment [5]; the authors projected that some PLWHIV
would maintain suppression for decades without treat-
ment change. However, few studies have evaluated long-
term viral suppression using a single combination.
We estimated rates of virological failure, treatment
interruption and treatment switches for PLWHIV with
initial viral suppression on first-line EFVþTDFþFTC/
3TC within a multinational collaboration of European
HIV cohort studies. We evaluated demographic and
clinical risk factors for these events.Methods
We analysed data, merged in June 2015, from 20 cohorts
in the Collaboration of Observational HIV Epidemio-
logical Research Europe (COHERE) [6]. Additional data
were added from the UK CHIC September 2016 dataset,
to align last recorded follow-up with other cohorts.
PLWHIV were included if they were ART-naı¨ve at
cohort enrolment and started first-line EFVþTDFþ
FTC/3TC at age at least 16 years with viral suppression
(defined as one measurement undetectable or <200
copies/ml) within 9 months. Initial regimen was ignored
if it changed within 1 week of first treatment. PLWHIV
were excluded if their last viral load measurement was
less than 9 months after starting ART, if treatment was
interrupted before viral suppression or if at least one pre-
ART viral load measurement was either undetectable or
50 copies/ml within 1 year prior to starting ART (to
remove those who may have started ART before the daterecorded). COHERE cohorts with fewer than 20
PLWHIV meeting the inclusion criteria were dropped.
Statistical analysis
Follow-up started at the date of viral suppression.
Virological failure was defined as one measurement
 200 copies/ml to allow consistency of analysis across
cohorts and over the timespan considered. Treatment
interruption was defined as cessation of all ART, but
interruptions of up to 1 week were ignored. We also
estimated rates of virological failure whilst on
EFVþTDFþ FTC/3TC, of complete interruption of
ART directly from treatment with EFVþTDFþFTC/
3TC and of switching from EFVþTDFþ FTC/3TC to
any other regimen.
Piecewise exponential time-to-event models were used
to estimate event rates, which were estimated for yearly
intervals from initial viral suppression, with a single rate
estimated for follow-up more than 9 years. Rates were
first estimated without adjustment for patient character-
istics. For virological failure and treatment interruption,
cause-specific piecewise exponential models were fitted
with censoring for the other event (i.e. only the first
virological failure or interruption event was counted):
these were used to estimate the rates and cumulative
incidence of each event, accounting for the competing
risk of the other [7].
We estimated adjusted associations of the virological
failure and treatment interruption outcomes with patient
sex, mode of acquisition (MSM [reference], female
heterosexual, male heterosexual, female IDU, male IDU),
ethnicity (white [reference], Black, Asian, other), prior
AIDS diagnosis, baseline CD4þ cell count (0–200
[reference], 200–350, 350–500, >500 cells/ml) and
viral load (0–20k, 20k–100k [reference], 100k–500k,
>500k copies/ml), time-updated age (<25, 25–35, 35–
45 [reference], 45–55, >55 years), year of starting ART
(2002–2004, 2005–2006, 2007–2008, 2009–2010 [ref-
erence], 2011–2012, 2013–2014) and cohort. For five
cohorts, ethnicity was not recorded so this variable was set
to reference (i.e. ‘white’) for the purpose of multivariable
analysis. For categorical variables, the group with highest
frequency was chosen as reference. Baseline CD4þ cell
counts and viral load were defined as the last measurement
obtained within the 6-month period before ART start.
Follow-up was censored at 6 months after last recorded
viral load or at death. The adjusted analyses were
conducted without censoring at switch to other ART
regimen.
For analyses adjusted for patient characteristics, full
covariate data were available in 83.0% of cases (ignoring
ethnicity for cohorts without this information recorded).
Multiple imputation using chained equations was
implemented using the Stata ‘ice’ package [8], with 17
imputed datasets for each event [9]. Imputation models
Long-term viral suppression Stirrup et al. 747included log event times and indicators for cohorts and
events. Predictive mean matching was employed for
baseline CD4þ, viral load and age. Imputation models
used square root CD4þ cell counts and log10 viral load.
MSM status, sex and IDU status were imputed separately;
these factors were then combined for analysis models with
IDU status considered the primary mode of acquisition
in PLWHIV who were also MSM. PLWHIV with
transfusion-related or ‘other’ acquisition were excluded
due to low numbers.Results
The study population included 19 527 PLWHIV (Fig. S1,
http://links.lww.com/QAD/B421). The majority mode
of acquisition was MSM (59.6%). Where known, white
ethnicity was most common (70.2%) with 20.6% Black
and 4.2%Asian ethnicities (further details in Tables S1 and
S2, http://links.lww.com/QAD/B421).
Unadjusted incidence rates of virological failure and
ART interruption according to years since initial viral
suppression are shown in Fig. 1a and b. For these analyses
(counting only the first event), there were 2655 (13.6%)
virological failure events and 1521 (7.8%) treatment
interruption events, and median (interquartile range)
follow-up was 3.7 (2.0–5.6) years. For analyses restricted
to those remaining on EFVþTDFþFTC/3TC, inci-
dence rates are shown in Fig. 1c and d: there were 1879
(9.6%) virological failure outcomes and 1062 (5.4%)
treatment interruption outcomes. Results in supplemen-
tary material show rates of switching from
EFVþTDFþ FTC/3TC to any other ART regimen,
the combined incidence of ‘virological failure or
treatment interruption’ (Fig. S2, http://links.lww.com/
QAD/B421), and cumulative incidence functions for
virological failure and ART interruption (Fig. S3, http://
links.lww.com/QAD/B421).
Fifty-five PLWHIV with transfusion-acquired HIV and
262 with ‘other’ acquisition were excluded from
multivariable analyses. Adjusted associations of patient
characteristics with virological failure and treatment
interruption are shown in Table 1. MSM had lowest rates
of virological failure and treatment interruption while
IDU hadmarkedly higher rates of treatment interruption.
Black ethnicity was associated with higher rates of
virological failure and treatment interruption. A prior
AIDS diagnosis was associated with higher rates of
virological failure but lower rates of treatment interrup-
tion. Baseline CD4þ cell count more than 200 cells/ml
was associated with lower rate of virological failure, but
those with baseline CD4þ above 500 cells/ml had higher
rates of treatment interruption. Rates of virological
failure increased with increasing baseline viral load, but
there was little evidence that baseline viral load wasassociated with treatment interruption. Rates of both
virological failure and treatment interruption declined in
later compared with earlier calendar years of starting
ART. Age below 35 years was associated with a higher
rate of virological failure and of treatment interruption.Discussion
Amongst PLWHIV enrolled in a large collaboration of
European cohort studies starting first-line EFVþTDFþ
FTC/3TC, rates of virological failure and treatment
interruption declined over 3 years following initial
virological suppression before stabilizing at low levels:
the subsequent combined incidence rate of virological
failure or treatment interruption was below 4/100
person-years for PLWHIV remaining on ART, and was
below 3.5/100 person-years considering only those on
the EFVþTDFþFTC/3TC regimen.
The regimen included in this analysis, EFVþTDFþ
FTC/3TC, is no longer preferred first-line ART in most
patients: WHO now recommends dolutegravir-based
ART [2] following evidence that this has improved
efficacy and reduced side effects [10]. Tenofovir
alafenamide may also have a better side effect profile
than TDF in some combinations [11]. However, whilst
agreements are in place to provide dolutegravir-based
ARTat low cost in LMICs [4], EFVþTDFþFTC/3TC
is available as a low-cost generic option worldwide and
there is not strong evidence for an individual-level benefit
of switching off this regimen in virologically suppressed
patients [4]. At present, there are also concerns regarding
the use of dolutegravir in women who may become
pregnant [12].
We found lower rates of both virological failure and
treatment interruption for PLWHIV on first-line
EFVþTDFþ FTC/3TC in comparison to UK patients
starting any 3þ drug ART [5], for whom a combined
incidence of around 12.5/100 person-years was reported
in the first year from baseline (c. 9.0/100 person-years)
dropping to less than 6/100 person-years beyond 3 years
(c.<4/100 person-years). Long-term studies have not yet
been published regarding the durability of viral suppres-
sion on first-line dolutegravir-based ART, but as there is
evidence from trials of superior viral suppression on
dolutegravir vs. EFV at 48, 96 and 144 weeks [13] it is
likely that our results reflect an upper limit on the
virological failure rates that would be expected for
equivalent patients on dolutegravir-based ART.
Black ethnicity was associated with virological failure and
treatment interruption, which is consistent with the
findings of O’Connor et al. [5] for the United Kingdom.
Non-MSM groups were also at higher risk of these
events, with particularly strong associations for IDUs as
748 AIDS 2019, Vol 33 No 4
●
●
●
●
● ●
●
● ●
●
1171 562 322 230 160 101 50 32 19 8
18547 16232 13231 10394 7722 5164 3106 1800 1058 797
●
●
●
● ●
●
●
●
●
●
926 386 210 140 100 52 36 14 13 2
16126 12884 9904 7424 5289 3390 1966 1100 629 457
●
●
● ● ● ●
● ●
●
●
508 370 215 161 116 76 35 22 14 4
18547 16232 13231 10394 7722 5164 3106 1800 1058 797
●
●
● ● ● ●
● ● ●
●
399 266 147 101 73 47 15 8 5 1
16126 12884 9904 7424 5289 3390 1966 1100 629 457
VF on EFV+TDF+FTC/3TC (censor at interruption, switch, LTFU, death) Trt interrupt on EFV+TDF+FTC/3TC (censor at VF, switch, LTFU, death)
VF on ART (censor at interruption, LTFU, death) Trt interruption (censor at VF, LTFU, death)
0−1 1−2 2−3 3−4 4−5 5−6 6−7 7−8 8−9 >9 0−1 1−2 2−3 3−4 4−5 5−6 6−7 7−8 8−9 >9
0−1 1−2 2−3 3−4 4−5 5−6 6−7 7−8 8−9 >9 0−1 1−2 2−3 3−4 4−5 5−6 6−7 7−8 8−9 >9
0
1
2
3
4
5
6
7
0
1
2
3
4
5
6
7
0
1
2
3
4
5
6
7
0
1
2
3
4
5
6
7
Years since initial viral suppression
E
st
im
at
ed
 in
ci
de
nc
e 
(/1
00
 p
er
so
n−
ye
ar
s)
(a) (b)
(c) (d)
Fig. 1. Plots of unadjusted incidence rate estimates (per 100 person-years) according to years since initial viral suppression for
virological failure (VF) and treatment interruption (censoring at VF) whilst on any antiretroviral therapy [(a) and (b)], and whilst
on efavirenz R tenofovir R emtricitabine/lamivudine [(c) and (d), respectively]. Virological failure defined as any viral load
observation  200 copies/ml. Loss to follow-up (LTFU) defined in terms of virological monitoring, with censoring 6 months after
last recorded viral load measurement. Error bars show 95% confidence interval for estimates. The number of events for each time
period is given directly below each plot, whilst the ‘person-years at risk’ for each period is given below that (gray text).found previously [14]. Rates of virological failure among
non-white and non-MSM individuals may vary between
countries and healthcare settings, but these findings
reinforce the need to identify subpopulations with worse
outcomes on ART [15] and understand the underlying
causes. Both ethnicity and mode of acquisition are
associated with social and economic factors whichthemselves may vary between cohorts. Age less than 35
was associated with higher rates of virological failure and
treatment interruption, consistent with previous findings
in both high income [5,14] and LMIC [16] settings.
Differences in rates of virological failure between
demographic groups are likely to be driven by adherence
[17].
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Table 1. Adjusted (for other characteristics in the table) associations (incidence rate ratios) of patient characteristics with virological failure and
treatment interruption.
VF on ART
(censor at interruption, LTFU, death)
Treatment interruption
(censor at VF, LTFU, death)
n Patients n Events IRRa (95% CI) P valueM n Events IRRa (95% CI) P valueM
ART regimen On FTC 17945 2256 1 [Reference] 0.140 1322 1 [Reference] 0.710
On 3TC 1265 340 1.13 (0.96, 1.34) 165 1.05 (0.83, 1.32)
Mode of acquisitionb MSM 12399 1467 1 [Reference] <0.001 825 1 [Reference] <0.001
Hetero (female) 2750 453 1.19 (1.05, 1.35) 271 1.17 (0.99, 1.39)
Hetero (male) 3486 577 1.32 (1.18, 1.47) 303 1.26 (1.08, 1.47)
IDU (female) 123 17 1.15 (0.70, 1.89) 20 3.18 (2.00, 5.04)
IDU (male) 451 82 1.53 (1.21, 1.94) 68 3.13 (2.40, 4.08)
Ethnicityb,c White 8226 1015 1 [Reference] <0.001 627 1 [Reference] <0.001
Asian 484 63 1.12 (0.86, 1.45) 32 0.85 (0.59, 1.23)
Black 2363 435 1.33 (1.16, 1.53) 331 1.54 (1.29, 1.82)
Other 575 56 0.83 (0.63, 1.09) 55 1.03 (0.78, 1.37)
Prior AIDS Dx No 16803 2124 1 [Reference] 0.001 1298 1 [Reference] 0.059
Yes 2407 472 1.20 (1.08, 1.34) 189 0.85 (0.72, 1.01)
Baseline CD4þ cell
count (cells/ml)b
0–200 8879 1417 1 [Reference] 0.005 673 1 [Reference] <0.001
200–350 6432 838 0.90 (0.82, 0.99) 514 0.97 (0.85, 1.10)
350–500 2707 238 0.77 (0.67, 0.90) 199 1.17 (0.98, 1.39)
Over 500 1191 103 0.89 (0.72, 1.11) 101 1.60 (1.28, 2.01)
Baseline VL (copies/ml)b 0–20k 4580 416 0.72 (0.64, 0.82) <0.001 362 0.88 (0.76, 1.01) 0.262
20k–100k 6696 824 1 [Reference] 534 1 [Reference]
100k–500k 6130 997 1.28 (1.16, 1.42) 456 0.98 (0.86, 1.12)
Over 500k 1805 358 1.53 (1.34, 1.74) 135 1.03 (0.85, 1.26)
Start of ART 2002–2004 847 259 1.64 (1.35, 2.01) <0.001 137 1.52 (1.16, 2.00) 0.009
2005–2006 2000 460 1.34 (1.18, 1.53) 226 1.15 (0.96, 1.37)
2007–2008 4137 683 1.14 (1.03, 1.27) 387 1.10 (0.96, 1.27)
2009–2010 6058 732 1 [Reference] 443 1 [Reference]
2011–2012 4763 381 0.85 (0.75, 0.97) 247 0.94 (0.80, 1.11)
2013–2014 1405 81 0.86 (0.68, 1.09) 47 0.78 (0.57, 1.07)
Time-updated age (years)d Under 25 912 118 1.10 (0.87, 1.38) 0.007 102 1.90 (1.48, 2.44) <0.001
25–35 5613 765 1.16 (1.05, 1.28) 478 1.19 (1.04, 1.35)
35–45 7127 982 1 [Reference] 534 1 [Reference]
45–55 3933 513 0.97 (0.88, 1.08) 279 0.89 (0.78, 1.02)
Over 55 1625 218 0.95 (0.82, 1.09) 94 0.79 (0.64, 0.96)
3TC, lamivudine; ART, antiretroviral therapy; CI, confidence interval; Dx, diagnosis; FTC, emtricitabine; IRR, incidence rate ratio; LTFU, lost to
follow-up; VF, virological failure; VL, viral load.
aEstimated using Poisson regression models with adjustment for cohort and all variables listed in this table.
bMultiple imputation used for missing data.
cMultiple imputation not used for ethnicity in cohorts with no data on this variable: ethnicity was set to reference and these cohorts have not been
included in ethnicity rows of n patients and n events in this table.
dn Patients and n events are given according to baseline age at start of ART.
MUnivariate or multivariate Wald test.Consistent with previous literature [5,18] viral load
before starting treatment was associated with rates of
virological failure on treatment, whilst baseline CD4þ
cell count more than 200 cells/ml was associated with a
lower rate of virological failure on treatment [19].
PLWHIV with the highest baseline CD4þ cell counts
(>500 cells/ml) had highest rate of treatment inter-
ruption, consistent with previous studies [19,20], which
could reflect differences in behaviour and clinical
counselling for PLWHIV at lower immediate risk of
HIV-related morbidity. Most data in this analysis were
from the period before European guidelines recom-
mended starting ART in all PLWHIV irrespective of
CD4þ cell count.
Rates of virological failure and treatment interruption for
PLWHIV declined in later compared with earlier calendaryears of ART initiation. This may be linked to a reduction
in pill count as combination tablets became available [21],
but a limitation of our analysis is that we do not have
detailed information on combination dosing (e.g.
number of pills/day). Another limitation is that we
cannot determine whether treatment switching from
first-line regimen was driven by side effects.
We have quantified long-term virological suppression
achieved using first-line EFVþTDFþ FTC/3TC across
a large multinational cohort collaboration. This regimen
remains in use worldwide, so the low failure rate with
sustained virological suppression for up to a decade on
treatment is encouraging. The substantial differences in rates
of virological failure and treatment interruption according
to demographic and clinical characteristics may be useful for
targeted monitoring and adherence interventions.
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